West Pharmaceutical Reports Q4 and Full-Year 2023 Results, Provides 2024 Guidance

Details

Adjusted diluted EPS for Q4 grew by 3.4% and decreased by 5.8% for the full year. The company also introduced full-year 2024 financial guidance with net sales expected between $3.000 billion and $3.025 billion and adjusted diluted EPS in the range of $7.50 to $7.75. Management noted strong organic sales growth in 2023, driven by high-value product components and devices, and expects moderated organic sales growth in 2024.

Items reported

Exhibits (2)

About West Pharmaceutical Services Inc.

West Pharmaceutical Services Inc. is a leading global provider of innovative solutions for injectable drug administration. The company specializes in designing and manufacturing packaging and delivery systems specifically for pharmaceuticals, biologics, and vaccines. West Pharmaceutical Services plays a crucial role in ensuring the safety and efficiency of drug delivery through its products, which include stoppers, seals, containers, and pre-fillable syringe systems. Catering to a diverse range of healthcare and pharmaceutical clients, the company's offerings are integral in the development and distribution of injectable therapies across various therapeutic categories, including oncology, diabetes, and infectious diseases. As a partner to some of the world's leading pharmaceutical companies, West Pharmaceutical Services contributes significantly to advancements in medical treatments and healthcare technologies globally. Its commitment to quality and innovation underscores its importance in the pharmaceutical supply chain and enhances drug efficacy, ultimately impacting patient care and treatment outcomes.